Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study

Abstract  Objective: To evaluate the incidence, clinical features, and prognosis of pulmonary complications associated with toxic epidermal necrolysis
Design: Prospective study.
Setting: Dermatology intensive care unit in Mondor Hospital, France.
Patients: 41 consecutive patients.
Interventions: On admission, then daily, respiratory evaluation was based on clinical examination, chest X-ray, and arterial blood gas analysis. When clinical symptoms, X-ray abnormalities, or hypoxemia [partial pressure of oxygen (PO2) < 80 mm Hg] were present, fiberoptic bronchoscopy was performed.
Results: 10 patients presented early manifestations: dyspnea (n = 10), bronchial hypersecretion (n = 7), marked hypoxemia (n = 10) (PO2 = 59 ± 8 mm Hg). Chest X-ray was normal (n = 8) or showed interstitial infiltrates (n = 2). In these 10 patients, fiberoptic bronchoscopy demonstrated sloughing of bronchial epithelium in proximal airways. Delayed pulmonary complications occurred in 6 of these 10 patients from day 7 to day 15: pulmonary edema (n = 1), atelectasis (n = 1), bacterial pneumonitis (n = 4). Mechanical ventilation was required in 9 patients. A fatal outcome occurred in 7 patients. Seven patients did not develop early pulmonary manifestations (PO2 on admission 87 ± 6 mm Hg) but only delayed pulmonary symptoms related to atelectasis (n = 1), pulmonary edema (n = 4), and bacterial pneumonitis (n = 3); bronchial epithelial detachment was not observed. None of them required mechanical ventilation and all recovered with appropriate therapy.
Conclusions: "Specific" involvement of bronchial epithelium was noted in 27% of cases and must be suspected when dyspnea, bronchial hypersecretion, normal chest X-ray, and marked hypoxemia are present during the early stages of toxic epidermal necrosis. Bronchial injury seems to indicate a poor prognosis, as mechanical ventilation was required for most of these patients and was associated with a high mortality.

Key words  Toxic epidermal necrolysis • Stevens-Johnson syndrome • Pulmonary complications • Fiberoptic bronchoscopy • Bronchial epithelial necrosis
**Introduction**

In 1956, Lyell reported four cases of a skin eruption resembling scalding and related to either drug toxicity, staphylococcal infection, or undetermined etiology [1]. In fact, this original article included three different diseases corresponding to staphylococcal scalded skin syndrome, generalized fixed eruptions due to drugs, and toxic epidermal necrolysis (TEN) [2, 3]. With further cases and larger series, it became generally accepted that TEN was a drug-induced skin reaction. The main drugs incriminated in TEN are antibacterial sulfonamides, anticonvulsants, some nonsteroidal anti-inflammatory agents, and allopurinol [4–6]. In a few cases, TEN has been demonstrated to be related to *Mycoplasma* infection [7] or graft-versus-host disease (GVH) [8]. TEN is characterized by extensive epidermal detachment with mucous membrane involvement (Fig. 1), whereas the Stevens-Johnson syndrome (SJS) corresponds to a mild form of TEN with predominant mucosal involvement but epidermal detachment affecting less than 10% of the body surface area. TEN is rare since its incidence is estimated to be in the range of 1 to 1.5 cases/million per year. However, it is a life-threatening disease, fatal in 30% of cases, and death is mainly related to sepsis or visceral involvement such as gastrointestinal or pulmonary complications [9, 10]. Pulmonary manifestations have been poorly studied but appear to be heterogeneous, including specific bronchial mucosal necrosis, pulmonary edema, and infectious pneumonitis, as described in a few isolated case reports or rare postmortem studies [11–15]. The aim of the present study was therefore to evaluate the incidence of pulmonary manifestations in TEN, to define their clinical characteristics, and to determine their prognosis in a large prospective series.

**Patients and methods**

**Patients**

Forty-one consecutive patients admitted to our Dermatological Intensive Care Unit (Henri Mondor Hospital, Créteil, France) with epidermal detachment affecting more than 10% of the body surface area (BSA) were enrolled in the study from January 1992 to September 1995. Cases of TEN associated with human immunodeficiency virus infection, *Mycoplasma* pneumonitis, or GVH disease were not included. Patients were clinically classified as overlap SJS-TEN when the epidermal detachment ranged from 10 to 30% of BSA and as TEN when the epidermal detachment exceeded 30% of BSA [16]. The diagnosis was confirmed by a skin biopsy showing detachment of full thickness epidermis and/or total epidermal necrosis. Drug causality was assessed according to the official method of the French Pharmacovigilance Centers [17].

On the day of admission, then daily, respiratory monitoring was performed, based on clinical examination, chest X-ray, and arterial blood gas analysis. When clinical symptoms were present, such as polyneumia (respiratory rate > 30 breaths/min) or bronchial hyperterection, and were associated with X-ray abnormalities or hypoxemia (partial pressure of oxygen (PO2) < 80 mm Hg in room air), a diagnostic procedure using fiberoptic bronchoscopy (FOB) was performed. Four patients were excluded from the study due to previous chronic obstructive pulmonary disease (n = 3) or chronic heart failure (n = 1) associated with a low baseline PO2. In these cases, PO2 values on admission were 68 ± 4 mm Hg but remained unchanged after recovery. FOB was not performed despite a PO2 < 80 mm Hg on admission. The study group therefore consisted of 37 patients.

**FOB and associated procedures**

Bronchoscopy was performed using an Olympus BF P30 fiberoptic bronchoscope (Olympus, France) in the usual manner. After endobronchial examination, bacterial analysis was performed according to the Plugged Telescoping Catheter (PTC) procedure, using a PTC unit (Combicath S828.20; Plastimed Lab, Saint-Leu la Forêt, France) [18]. A positive culture was defined as the recovery of > 103 colony-forming units/ml of a potential pathogen. When bronchial mucosa detachment was present, repeated FOBs were performed in order to aspirate epithelial fragments.

For each patient, at least three bronchial biopsy specimens were taken at different levels in the right bronchial tract. Samples were fixed by immersion in Bouin’s solution and then paraffin embedded or fixed by 2.5% glutaraldehyde in 0.045 M cacodylate buffer, pH 7.4 for semithin section processing.

**Ancillary studies**

Blood cell count, blood cultures, and serological studies for *Mycoplasma* were performed routinely for each patient. Skin bacterial samples were cultured on petri dishes every 48 h. Pulmonary function was monitored by repeated blood arterial gas analyses during the course of TEN.

**Patient classification according to pulmonary manifestations**

Patients were classified into three groups according to pulmonary manifestations: group 1 comprised patients with no pulmonary manifestations on admission or during the course of the disease; group 2 had patients with pulmonary manifestations during the
Table 1 Clinical characteristics of the study patients (+ Deceased patients, BSA body surface area, TEN toxic epidermal necrolysis, SJS Stevens-Johnson syndrome, TMP-SMX trimethoprim-sulfamethoxazole, ND not determined) (Pulmonary edema, Bacterial pneumonitis in full in column 8)

| Patients | Age (years) | Sex | Offending drug       | Skin feature | % BSA | Early pulmonary complications | Delayed pulmonary complications | PO2 in room air |
|----------|-------------|-----|----------------------|--------------|-------|-------------------------------|---------------------------------|----------------|
| Group 1  |             |     |                      |              |       |                               |                                 |                |
| 1        | 25          | F   | Salazosulfapyridine  | SJS/TEN      | 10    | Absent                        | Absent                          | 105            |
| 2        | 14          | F   | Carbamazepine        | SJS/TEN      | 15    | -                             | -                               | 90             |
| 3        | 16          | M   | Adiazine             | TEN          | 35    | -                             | -                               | 91             |
| 4        | 30          | F   | Carbamazepine        | TEN          | 35    | -                             | -                               | 99             |
| 5        | 20          | F   | Depamide             | TEN          | 40    | -                             | -                               | 108            |
| 6        | 85          | M   | TMP-SMX              | SJS/TEN      | 15    | -                             | -                               | 88             |
| 7        | 25          | M   | Menterol             | SJS/TEN      | 20    | -                             | -                               | 88             |
| 8        | 14          | M   | TMP-SMX              | TEN          | 60    | -                             | -                               | 98             |
| 9        | 61          | F   | TMP-SMX              | TEN          | 35    | -                             | -                               | 90             |
| 10       | 14          | F   | Chloromamine         | SJS/TEN      | 15    | -                             | -                               | 106            |
| 11+      | 85          | F   | TMP-SMZ              | TEN          | 30    | -                             | -                               | 90             |
| 12       | 45          | F   | ND                   | SJS/TEN      | 15    | -                             | -                               | 105            |
| 13       | 41          | F   | Piroxicam            | SJS/TEN      | 10    | -                             | -                               | 90             |
| 14       | 39          | F   | TMP-SMZ              | SJS/TEN      | 20    | -                             | -                               | 92             |
| 15+      | 43          | M   | Allopurinol          | TEN          | 75    | -                             | -                               | 113            |
| 16+      | 56          | M   | ND                   | TEN          | 35    | -                             | -                               | 90             |
| 17       | 36          | F   | ND                   | SJS/TEN      | 20    | -                             | -                               | 90             |
| 18       | 57          | F   | Chloromazine         | TEN          | 30    | -                             | -                               | 95             |
| 19       | 54          | M   | Ceftriaxone          | SJS/TEN      | 20    | -                             | -                               | 85             |
| 20       | 54          | F   | Fenofibrate          | TEN          | 40    | -                             | -                               | 89             |
| Group 2  |             |     |                      |              |       |                               |                                 |                |
| 21+      | 72          | F   | ND                   | SJS/TEN      | 20    | -                             | Death                           | 50             |
| 22+      | 76          | F   | Amaxocilin           | SJS/TEN      | 15    | -                             | Death                           | 64             |
| 23+      | 36          | F   | ND                   | SJS/TEN      | 25    | Bronchial epithelial necrosis | Pulmonary edema                 | 55             |
| 24+      | 45          | M   | Piroxicam            | TEN          | 100   | -                             | Death                           | 72             |
| 25+      | 55          | M   | Phenobarbital        | SJS/TEN      | 20    | -                             | Bacterial pneumonitis            | 54             |
| 26+      | 50          | M   | Salazopyrine         | TEN          | 40    | (n = 10)                      | Bacterial pneumonitis            | 54             |
| 27       | 26          | F   | Ibuprofen            | TEN          | 60    | -                             | Atelectasis                      | 64             |
| 28       | 16          | F   | Fluvoxamine          | TEN          | 60    | -                             | Bacterial pneumonitis            | 65             |
| 29+      | 32          | F   | Chloromazine         | TEN          | 30    | -                             | Bacterial pneumonitis            | 65             |
| 30       | 43          | M   | Phenobarbital        | TEN          | 70    | -                             | Pulmonary edema/bacterial pneumonitis | 60             |
| Group 3  |             |     |                      |              |       |                               |                                 |                |
| 31       | 43          | F   | Phenobarbital        | TEN          | 35    | Absent                        | Pulmonary edema                 | 90             |
| 32       | 33          | F   | Paroxetine           | TEN          | 35    | -                             | Pulmonary edema                 | 98             |
| 33       | 48          | M   | Carbamazepine        | SJS/TEN      | 25    | -                             | Bacterial pneumonitis            | 85             |
| 34       | 37          | M   | Allopurinol          | TEN          | 40    | -                             | Atelectasis                      | 86             |
| 35       | 59          | F   | Allopurinol          | TEN          | 50    | -                             | Pulmonary edema/bacterial pneumonitis | 85             |
| 36       | 36          | F   | Depamide             | SJS/TEN      | 25    | -                             | Bacterial pneumonitis            | 80             |
| 37       | 53          | M   | Carbamazepine        | TEN          | 40    | -                             | Pulmonary edema                 | 85             |

Results

Study population

Altogether, 73% of patients were admitted from other French hospitals, as our dermatology unit is considered as a national reference center. The delay between the first mucocutaneous symptoms and admission to our center was in the range of 1 to 4 days. Table 1 summarizes the clinical features and lists the offending drugs in the 37 patients studied. There were 14 males and
23 females, with a mean age of 42 ± 19 years (range 14–85 years). Sixteen patients were classified as overlap SJS-TEN and the remaining 21 patients were classified as TEN. Overlap SJS-TEN and TEN were related to an adverse drug reaction in 32 patients and in 5 patients the cause was not determined. BSA involvement was 10 to 100 % (mean 34 ± 20 %). Mucous membrane lesions in the oral cavity were associated with skin lesions in all patients.

Patients without pulmonary manifestations (group 1)

Of the 37 patients, 20 were classified as group 1 [54 %; 95 % confidence interval (CI) 37–70 %]. The mean age in this group was 41 ± 22 years. The mean BSA involvement was 29 ± 17 % (range 10–75 %). All patients had associated oropharyngeal mucosal lesions. Chest X-ray was normal and arterial PO$_2$ was 95 ± 8 mm Hg on admission and remained in the normal range during the course of TEN. Three patients in this group died of septic shock during the course of TEN.

Early pulmonary manifestations (group 2)

Clinical features

Of the 37 patients, 10 were classified as group 2 (27 %; 95 % CI 14–44 %) (Table 1). The mean age in this group was 45 ± 19 years. The delay between first symptoms and admission was in the range of 1 to 3 days. The mean BSA involvement was 44 ± 28 % (range 15–100 %). All patients presented with respiratory symptoms on admission. Dyspnea associated with increased respiratory rate was a constant clinical feature. Bronchial hypersecretion was observed in 7 of the 10 patients. Hypersecretion was abundant and appeared as a yellow, fluid, transparent sputum without any purulence, as demonstrated by sputum cytological examination. None of the patients in this group had evidence of bronchial casts in their sputum. Chest X-ray was normal in 8 patients but showed interstitial infiltrates in 2 patients. Blood gas analysis in room air during the first 48 h revealed a marked hypoxemia with a mean PO$_2$ of 59 ± 8 mm Hg (range 47–72 mm Hg) associated with respiratory alkalosis. PO$_2$ values on admission in group 2 were significantly lower than in groups 1 or 3 ($p < 0.0001$).

FOB results

Bronchoscopy examination revealed a pattern of diffuse loss of bronchial epithelium involving the proximal airways. Patients were investigated during the first 48 h after admission, corresponding to day 3 to 4 from the onset of skin manifestations. Mucosal detachment involved up to 50 % of bronchial mucosa by the first examination and was close to 100 % of bronchial surface area at later stages. Bronchial involvement was characterized, in the early stages, by areas of white ground-glass appearance, evolving toward areas of red denuded mucosa associated with the presence of bronchial casts. At later stages, the confluence of bronchial ulcerations contributed to form a diffuse abrasive pattern (Fig. 2). Protected bronchial sampling remained sterile in every case.

Histologic findings

Bronchial biopsies confirmed epithelial necrosis as suggested macroscopically by large ulcerations or complete abrasion of bronchial epithelium. The lamina propria was only lined with denuded basement membrane and the inflammatory features were the presence of numerous infiltrating mononuclear cells, including lymphocytes, monocytes, and plasma cells, and by dilatation of small vessels (Fig. 3). There was no evidence of histologic criteria consistent with an infectious process such as predominant polymorphonuclear cell infiltration or multinucleated giant cells suggesting viral infection. Repeated FOB and biopsies were performed during the course of TEN in 3 surviving patients in group 2, allowing assessment of the time of re-epithelialization. Normal bronchial mucosa began to recover at the same time as skin re-
**Clinical data**

Seven of the 37 patients were classified as group 3 (19%; 95% CI: 8–35%) (Table 1). The mean age was 44 ± 10 years. The delay between first symptoms and admission was in the range of 2 to 5 days. The mean BSA involvement was 35 ± 9% (range 25–50%). The patients had no pulmonary manifestations on admission (mean PO$_2$ 87 ± 6 mmHg) but developed nonspecific pulmonary manifestations, including atelectasis ($n = 1$), pulmonary edema related to fluid overload ($n = 4$), and bacterial pneumonia ($n = 3$), from day 5 to day 10. One patient developed both pulmonary edema and bacterial pneumonitis. Bacterial pathogens isolated by the PTC procedure consisted of methicillin-resistant *Staphylococcus* ($n = 1$), *Acinetobacter baumanii* ($n = 1$), and *Streptococcus pneumoniae* ($n = 1$).

**FOB data**

Bronchoscopy examination was performed from day 5 to day 10. The macroscopic appearance of the mucosa was normal in all 7 patients.

**Histologic findings**

Three bronchial biopsies in each patient confirmed the absence of bronchial epithelial necrosis. In 2 patients, a mild polymorphonuclear cell infiltration was observed in the bronchial lamina propria and was related to associated bacterial pneumonitis, as demonstrated by the PTC procedure.

**Outcome**

None of the patients in group 3 required ventilatory support. All recovered from the delayed pulmonary complications with appropriate therapy.
Discussion

Pulmonary complications have been occasionally reported in the course of TEN in a few isolated cases [11-14]. However, to our knowledge, this study is the first prospective evaluation of respiratory tract involvement in a large series of patients with TEN. In our study, early pulmonary complications occurred in about 25 % of cases (95 % CI 14-44 %) and corresponded to bronchial mucosal sloughing, as demonstrated by FOB. Respiratory symptoms related to bronchial epithelium detachment developed within the 4 days after the onset of mucocutaneous symptoms.

Bronchial involvement in TEN does not appear to be correlated with the extent of epidermal detachment or with related offending drugs. In this series, and in most of the cases reported in the literature, dyspnea and bronchial hypersecretion are usually the first clinical symptoms. Interestingly, hypersecretion was present in 7 out of 10 patients and was characterized by a fluid, yellow, nonpurulent sputum, suggesting plasma exudation across the altered bronchial epithelial barrier. It is noteworthy that the chest X-ray was normal on admission in most cases but further X-rays soon revealed interstitial infiltrates highly suggestive of pulmonary edema. However, alveolar epithelial involvement was not established in this study as none of the patients who died of acute respiratory failure were autopsied.

In one case of TEN with multiple organ failure described in the literature, necrosis of the alveolar walls was reported but autopsy was performed after a long period of assisted ventilation and septic complications, raising the question of the specificity of these pathologic findings [13]. Other pulmonary manifestations related to bronchial mucosal involvement have been described elsewhere, including mild hemoptysis [12] or expectoration of bronchial mucosal casts, which seems highly suggestive of bronchial mucosal involvement [14]. In all cases, acute respiratory failure developed rapidly after the onset of skin detachment. In 6 cases in this series, respiratory distress was associated with severe hypoxemia (\( \leq 60 \text{ mm Hg} \)) at the time of admission and required immediate ventilatory support. In the remaining 4 cases, arterial \( \text{PO}_2 \) was moderately altered (ranging from 64 to 72 mm Hg) on admission but dropped dramatically during the following 24 h, justifying mechanical ventilatory assistance in 3 out of 4 patients.

Our results are in agreement with those previously reported since ventilatory support was required in all cases described in the literature [11-13]. Mechanical ventilation was used according to the recent consensus conference guidelines [19]. In patients with ARDS, volume-controlled ventilation using 7 to 10 ml/kg tidal volume was performed in order to keep the pressure plateau below 35 cm H\(_2\)O. Positioning of these patients (supine/prone) was not routinely performed since the benefit of this strategy has not been proved. Moreover, skin lesions made it difficult to turn these patients. In contrast, the 27 patients with no early respiratory symptoms or hypoxemia did not require ventilatory support in the course of the disease. However, in absence of respiratory symptoms, FOB was not performed and therefore we cannot exclude the possibility of bronchial involvement in group 1. Interestingly, FOB was performed in 7 patients who developed only delayed complications between day 5 and day 10 after the onset of TEN, an interval which would reasonably exclude the possibility of early re-epithelialization. No bronchial mucosal detachment was observed in these 7 patients. Such results therefore suggest that bronchial involvement is associated with early respiratory symptoms and marked hypoxemia developing simultaneously with or very soon after the onset of skin manifestations. Furthermore, bronchial mucosal involvement seems to be related to a poor prognosis, constituting a high risk factor for acute respiratory failure.

FOB appeared to be a simple procedure to identify bronchial mucosal detachment in TEN. Moreover, this study demonstrated a good correlation between the bronchoscopic appearance of the mucosa and histological lesions of the bronchial epithelium. In 10 patients with early pulmonary manifestations and the appearance of mucosal erosions at bronchoscopy, histological examination revealed large areas of epithelial necrosis identified at different levels of the bronchial tree, whereas in 7 patients with only delayed pulmonary complications, there was no evidence of bronchial detachment at bronchoscopy and bronchial biopsy specimens were normal. Histological findings were characterized by extensive necrosis of bronchial epithelium without any alteration of basement membrane or lamina propria. Cell alterations consistent with viral infection such as cell ballooning, viral inclusion, giant cells, or syncytia formation were absent. Moreover, bacterial analysis of bronchial protected samples remained negative, leading us to consider that an infectious process was unlikely. Interestingly, airway sloughing and skin detachment appeared to be synchronous and both regenerated over the same time interval, suggesting "specific" TEN bronchial epithelial involvement.

The basic mechanisms responsible for skin and/or bronchial mucosa necrosis in TEN remain unknown. Cell-mediated cytotoxicity has been suggested by infiltration of inflammatory cells in areas of epidermal necrosis [20, 21]. Among these cells, monocytes/macrophages and T-cell lymphocytes infiltrating dermis and epidermis could play a crucial role via local TNF\( \alpha \) and cytotoxic secretion [22-24]. It is noteworthy that the predominant inflammatory cells infiltrating bronchial mucosa in patients developing "specific" TEN bronchial mucosal involvement mainly consisted of mononuclear cells. Recent studies have emphasized the role of the...
toxicity of metabolites of offending drugs [25, 26]. Such variations of metabolism could be related to genetic susceptibility [26, 27]. Toxic and immunological mechanisms are not mutually exclusive, since cell-mediated cytotoxicity might develop against toxic metabolites [28].

Delayed pulmonary complications were observed in all surviving patients displaying bronchial epithelial detachment and in 25% of patients with no early pulmonary manifestations. They mainly consisted of pulmonary edema and infectious pneumonitis. The mechanisms of pulmonary edema were not clearly established in our series. Although alteration of the bronchopulmonary epithelial barrier can be suspected in patients with bronchial mucosal detachment, fluid overload seems to occur more frequently in pulmonary edema since treatment of TEN requires a large fluid intake, including water, electrolytes, and macromolecular solutions [5]. Moreover, fluid balance control is not easily obtained, since central venous pressure monitoring is avoided due to the risk of systemic infection [29].

Bacterial pneumonitis is another frequent complication of TEN. Interestingly, we found a good correlation between bacteria isolated from the skin and those isolated from lung samples by PTC. Such findings could be useful to treat bacterial pneumonitis empirically before complete identification of the pathogens responsible for pneumonitis. In conclusion, the present study indicates that bronchial epithelial necrosis occurs in about 25% of cases of TEN and corresponds to a specific TEN-related disorder. This bronchial involvement appears to be an index of poor prognosis, as demonstrated by the short-term progression toward acute respiratory failure and the frequent development of delayed complications. Therefore FOB appears to be useful in patients with suspected pulmonary complications: (i) to identify bronchial involvement, (ii) to evaluate the prognosis, and (iii) to eliminate associated pneumonitis using appropriate bacterial sampling. Moreover, bronchial aspiration during FOB prevents atelectasis produced by sloughing of bronchial epithelium. To our knowledge, there is no demonstrated specific treatment for TEN and obviously for bronchial involvement. Further prospective studies would be required to determine the value of early ventilatory support to reduce early mortality related to the progression of pulmonary complications.

References

1. Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68: 355–361
2. Lyell A (1979) Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol 100: 69–86
3. Roujeau JC, Stern RS (1994) Severe adverse cutaneous reactions to drugs. N Engl J Med 10: 1272–1284
4. Guillaume JC, Roujeau JC, Revuz J, Penso D, Touraine R (1987) The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 123: 1166–1170
5. Roujeau JC, Chosidow O, Saiag P, Guillaume JC (1990) Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 23: 1039–1058
6. Roujeau JC, Kelly JP, Naldi L, Rzani B, Stern RS, Anderson T et al (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333: 1600–1607
7. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC (1995) Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis 14: 558–559
8. Villada G, Roujeau JC, Cordonnier C, Bagot M, Kuentz M, Weschler J, Vernet J-P (1990) Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 23: 870–875
9. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne RC, Weschler J, Touaine R (1987) Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 129: 1160–1165
10. Chosidow O, Delchier JC, Chaumette MT, Weschler J, Wolkenstein P, Bourgault I, Roujeau JC, Revuz J (1991) Intestinal involvement in drug induced toxic epidermal necrolysis. Lancet 337: 928
11. Timsit JF, Mion G, Rouyer N, Le Guludec Y, Carsin H (1992) Bronchopulmonary distress associated with toxic epidermal necrolysis. Intensive Care Med 18: 42–44
12. Virant FS, Redding GJ, Novack AH (1984) Multiple pulmonary complications in a patient with Stevens-Johnson syndrome. Clin Pediatr 24: 412–413
13. Roujeau JC, Chosidow O, Saiag P, Guillaume JC (1990) Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 23: 1039–1058
14. Das Gupta A, O’Malley J, Mallya R, Williams JG (1994) Bronchial obstruction due to respiratory mucosal sloughing in toxic epidermal necrolysis. Thorax 49: 935–936
15. Wahle D, Beste DJ, Conley SF (1992) Laryngeal involvement in toxic epidermal necrolysis. Otolaryngol Head Neck Surg 107: 796–799
16. Bastuji-Garin S, Rzani B, Stern R, Shear N, Naldi L, Roujeau JC (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 129: 92–96
17. Moore N, Biour M, Paux G et al (1985) Adverse drug reaction monitoring: doing it the French way. Lancet II: 1056–1058
18. Pham LH, Bruin-Buisson C, Legrand P, Rauss A, Verra F, Brochard L, Lemaire F (1991) Diagnosis of nosocomial pneumonia in mechanically ventilated patients. Comparison of a plugged telescoping catheter with the protected specimen brush. Am J Respir Crit Care Med 143: 1055–1061
19. Slutsky AS (1994) Consensus conference on mechanical ventilation. Intensive Care Med 20: 150–152
20. Roujeau JC, Dubertret LL, Moritz S, Revuz J-P, Touraine R (1995) Bronchopulmonary involvement of macrophages in the pathology of toxic epidermal necrosis. Br J Dermatol 113: 425–430
21. Villada G, Roujeau JC, Clerici T, Bourgault I, Revuz J (1992) Immunopathology of toxic epidermal necrolysis. Arch Dermatol 128: 50–53
22. Paquet P, Nikkels A, Arrese J, Vanderkeken A, Pierard G (1994) Macrophages and tumor necrosis factor α in toxic epidermal necrolysis. Arch Dermatol 130: 605–608

23. Miayauchi H, Hosokawa H, Akaeda T, Iba H, Asada Y (1991) T-cell subsets in drug-induced toxic epidermal necrolysis. Arch Dermatol 127: 851–857

24. Correia O, Delgado L, Ramos JP, Resende C, Fleming Torrinha JA (1993) Cutaneous T-cell recruitment in toxic epidermal necrolysis. Arch Dermatol 129: 466–468

25. Friedmann PS, Strickland I, Pirmohamed M, Park K (1994) Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 130: 598–604

26. Wolkenstein P, Carrière V, Charue D, Bastuji-Garin, Revuz J, Roujeau JC, Beaune P, Bagot M (1995) Slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 5: 255–258

27. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M (1995) Metabolic predisposition to cutaneous adverse reactions. Arch Dermatol 131: 544–551

28. Chosidow O, Bourgault I, Roujeau JC (1994) Drug rashes. What are the targets of cell-mediated cytotoxicity? Arch Dermatol 130: 627–629

29. Revuz J, Roujeau J-C, Guillaume J-C, Penso D, Touraine R (1987) Treatment of toxic epidermal necrolysis. Arch Dermatol 123: 1156–1158